Trial Profile
Phase I Trial of BKM120 in Combination With Carboplatin and Pemetrexed in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 16 Sep 2016 Status changed from active, no longer recruiting to completed.
- 05 Nov 2015 Planned End Date changed from 1 Jan 2017 to 1 Oct 2016 as reported by ClinicalTrials.gov.
- 05 Nov 2015 Planned primary completion date changed from 1 Jan 2017 to 1 Oct 2016 as reported by ClinicalTrials.gov.